N-Boc-4-(3-溴苯基)哌啶 | 886362-62-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: N-Boc-4-(3-溴苯基)哌啶
• 中文别名: 4-(3-溴苯基)-1-哌啶甲酸叔丁酯；4-(3-溴苯基)-1-N-boc-哌啶
• 英文名称: tert-butyl 4-(3-bromophenyl)piperidine-1-carboxylate
• 英文别名: 4-(3-Bromo-phenyl)-1-N-Boc-piperidine
• CAS: 886362-62-5
• 化学式: C₁₆H₂₂BrNO₂
• 分子量: 340.26
• InChiKey: SDAPURUFUOOCTE-UHFFFAOYSA-N

物化性质

• 沸点：
  397.8±42.0 °C(Predicted)
• 密度：
  1.283

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(3-Bromo-phenyl)-1-n-boc-piperidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(3-Bromo-phenyl)-1-n-boc-piperidine
CAS number: 886362-62-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C16H22BrNO2
Molecular weight: 340.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-Boc-4-(3-溴苯基)哌啶 在 potassium phosphate 、 四(三苯基膦)钯 、 偶氮二甲酸二异丙酯 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.25h， 生成
  参考文献：
  名称：

  脑透性杀锥虫N-肉豆蔻酰转移酶抑制剂的设计与合成

  摘要：

  N-肉豆蔻酰转移酶 (NMT) 代表了寄生虫原生动物布氏锥虫( T. brucei ) 中的一个有希望的药物靶点，布氏锥虫是人类非洲锥虫病 (HAT) 或昏睡病的病原体。我们之前已经验证了T. brucei NMT 作为治疗 HAT 疾病 1 期和 2 期的有希望的药物靶点。我们报告了使用先前报道的 DDD85646 ( 1 ) 作为设计T. brucei NMT的一类强效脑渗透抑制剂的起点。

  DOI：

  10.1021/acs.jmedchem.7b01255
• 作为产物：
  描述：

  tert-butyl 4-(3-bromophenyl)-3,6-dihydropyridine-1(2H)-carboxylate 在 palladium 10% on activated carbon 作用下， 以 乙酸乙酯 为溶剂， 以96 %的产率得到N-Boc-4-(3-溴苯基)哌啶
  参考文献：
  名称：

  一种肉桂酸酰胺衍生物的合成及其制药应用

  摘要：

  本发明提供了一种肉桂酸酰胺衍生物，所述衍生物具备式I所述结构。本发明涉及式I所述结构化合物的制备与制药应用，如说明书中所定义。式I化合物以肉桂酸结构为母核进行结构修饰与优化，筛选的化合物具有明确且高效的癌症治疗效果，能够抑制肿瘤生长、加速细胞凋亡和抑制细胞活力，且不具有细胞毒性，因此在治疗用途的同时保证用药的安全性。本发明还涉及使用式I的化合物或者其药物可接受的盐或者与其他药物联合应用于多种非实体瘤与实体瘤的治疗，包括但不限于原发性或继发性癌症例如肝癌、肺癌、结肠癌等的治疗。式I：

  公开号：

  CN115368263A

文献信息

• [EN] TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE<br/>[FR] INHIBITEURS, À BASE DE TRIAZOLOPYRIDINE, DE LA MYÉLOPEROXYDASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2017040449A1

  公开（公告）日：2017-03-09

  The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

  本发明提供了化合物的结构式（I）：其中A如规范中定义，并包括任何此类新化合物的组合物。这些化合物是髓过氧化物酶（MPO）抑制剂和/或嗜酸性粒细胞过氧化物酶（EPX）抑制剂，可用作药物。
• [EN] PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY<br/>[FR] DÉRIVÉS DE PYRROLIDINE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, ET LEUR UTILISATION EN THÉRAPIE
  申请人：ABBVIE DEUTSCHLAND

  公开号：WO2014140310A1

  公开（公告）日：2014-09-18

  The present invention relates to pyrrolidine derivatives of formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.

  本发明涉及式(I)的吡咯烷衍生物，或其生理耐受盐。该发明涉及包含此类吡咯烷衍生物的药物组合物，以及利用此类吡咯烷衍生物进行治疗的用途。这些吡咯烷衍生物是GlyT1抑制剂。
• C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays
  作者：Yann-Vaï Le Bihan、Rachel M. Lanigan、Butrus Atrash、Mark G. McLaughlin、Srikannathasan Velupillai、Andrew G. Malcolm、Katherine S. England、Gian Filippo Ruda、N. Yi Mok、Anthony Tumber、Kathy Tomlin、Harry Saville、Erald Shehu、Craig McAndrew、LeAnne Carmichael、James M. Bennett、Fiona Jeganathan、Paul Eve、Adam Donovan、Angela Hayes、Francesca Wood、Florence I. Raynaud、Oleg Fedorov、Paul E. Brennan、Rosemary Burke、Rob L.M. van Montfort、Olivia W. Rossanese、Julian Blagg、Vassilios Bavetsias

  DOI：10.1016/j.ejmech.2019.05.041

  日期：2019.9

  profiling in two orthogonal target engagement assays revealed a significant reduction from biochemical to cell-based activity across multiple analogues; this decrease was shown to be consistent with 2OG competition, and suggests that sub-nanomolar biochemical potency will be required with C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-one compounds to achieve sub-micromolar target inhibition in cells.

  鉴定出在KDM4和KDM5亚家族之间不同的组蛋白底物结合位点上的残基。随后，设计了一个C8取代的吡啶并[3,4- d ]嘧啶-4（3 H）-一个系列，以合理利用组蛋白底物结合位点之间的这些残基差异，以提高对KDM4亚家族的亲和力。 -亚家族酶。特别地，靶向残基E169和V313（KDM4A编号）。另外，研究了柔性吡啶并嘧啶酮C8-取代基的构象限制。这些方法产生了有效且细胞渗透性的双重KDM4 / 5-亚家族抑制剂，包括19a（KDM4A和KDM5B Ki分别为0.004和0.007μM）。在两个正交的靶标参与试验中进行的复合细胞分析显示，多种类似物从生化活性到基于细胞的活性均显着降低。该下降表明与2OG竞争一致，并表明将C8取代的吡啶并[3,4- d ]嘧啶-4（3 H）-one化合物需要亚纳摩尔的生化能力才能达到亚微摩尔的目标细胞中的抑制作用。
• [EN] POSITIVE ALLOSTERIC MODULATORS OF MGLUR2<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DE MGLUR2
  申请人：MERCK SHARP & DOHME

  公开号：WO2011109277A1

  公开（公告）日：2011-09-09

  The present invention is directed to 5-substituted 1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide and 1,3-dihydro[1,2,5]thiadiazolo[3,4-b]pyridine 2,2,-dioxide derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及5-取代的1,3-二氢-2,1,3-苯并噻二唑-2,2-二氧化物和1,3-二氢[1,2,5]噻二唑并[3,4-b]吡啶-2,2-二氧化物衍生物，它们是代谢型谷氨酸受体的增强剂，特别是mGluR2受体，并且在治疗或预防与谷氨酸功能障碍相关的神经和精神疾病以及代谢型谷氨酸受体参与的疾病中非常有用。该发明还涉及含有这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及代谢型谷氨酸受体的疾病中的用途。
• Synthesis and Structure–Activity Relationship Studies of 4-((2-Hydroxy-3-methoxybenzyl)amino)benzenesulfonamide Derivatives as Potent and Selective Inhibitors of 12-Lipoxygenase
  作者：Diane K. Luci、J. Brian Jameson、Adam Yasgar、Giovanni Diaz、Netra Joshi、Auric Kantz、Kate Markham、Steve Perry、Norine Kuhn、Jennifer Yeung、Edward H. Kerns、Lena Schultz、Michael Holinstat、Jerry L. Nadler、David A. Taylor-Fishwick、Ajit Jadhav、Anton Simeonov、Theodore R. Holman、David J. Maloney

  DOI：10.1021/jm4016476

  日期：2014.1.23

  demonstrated role in skin diseases, diabetes, platelet hemostasis, thrombosis, and cancer. Herein, we report the identification and medicinal chemistry optimization of a 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide-based scaffold. Top compounds, exemplified by 35 and 36, display nM potency against 12-LOX, excellent selectivity over related lipoxygenases and cyclooxygenases, and possess favorable

  人类脂肪氧化酶 (LOX) 是一类含铁酶，可催化多不饱和脂肪酸氧化以提供相应的生物活性羟基二十碳四烯酸 (HETE) 代谢物。这些类二十烷酸信号分子参与了许多生理反应，例如血小板聚集、炎症和细胞增殖。我们小组对血小板型 12-( S )-LOX (12-LOX)产生了特别的兴趣，因为它在皮肤病、糖尿病、血小板止血、血栓形成和癌症中发挥了重要作用。在此，我们报告了基于 4-（（2-羟基-3-甲氧基苄基）氨基）苯磺酰胺的支架的鉴定和药物化学优化。顶级化合物，以35和36为例, 显示对 12-LOX 的 nM 效力，对相关脂肪氧化酶和环氧化酶具有出色的选择性，并具有良好的 ADME 特性。此外，这两种化合物均抑制 PAR-4 诱导的人血小板聚集和钙动员，并减少 β 细胞中的 12-HETE。